Addington, J., and Duchak, V. (1997). Reasons for substance use in schizophrenia. Acta Psychiatr Scand, 96, 329–333.CrossRefGoogle ScholarPubMed

Allebeck, P., Adamsson, C., Engstrom, A. et al. (1993). Cannabis and schizophrenia: A longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand, 88, 21–24.Google Scholar

Arndt, S., Tyrrell, G., Flaum, M., et al. (1992). Comorbidity of substance abuse and schizophrenia: The role of pre-morbid adjustment. Psychol Med, 22, 379–388.Google Scholar

Baigent, M., Holme, G., and Hafner, R. J. (1995). Self reports of the interaction between substance abuse and schizophrenia. Aust NZ J Psychiatry, 29, 69–74.Google Scholar

Baker, A., Lewin, T., Reichler, H., et al. (2002). Motivational interviewing among psychiatric in-patients with substance use disorders. Acta Psychiatr Scand, 106, 233–240.Google Scholar

Barkus, E., and Lewis, S. (2008). Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychol Med, 38, 1267–1276.CrossRefGoogle Scholar

Barkus, E., Stirling, J. Hopkins, R., et al. (2006). Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology, 39, 175–178.Google Scholar

Bhattacharyya, S., Wilson, R., Appiah-Kusi, E., et al. (2018). Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: A randomized clinical trial. JAMA Psychiatry, 75, 1107–1117.Google Scholar

Brandt, J. (1991). The Hopkins verbal learning test: Development of a new memory test with six equivalent forms. Clin Neuropsychologist, 5, 125–142.Google Scholar

Buhler, B., Hambrecht, M., Loffler, W., et al. (2002). Precipitation and determination of the onset and course of schizophrenia by substance abuse: A retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res, 54, 243–251.Google Scholar

Cantor-Graae, E., Nordstrom, L., and McNeil, T. (2001). Substance abuse in schizophrenia: A review of the literature and a study of correlates in Sweden. Schizophr Res, 48, 69–82.CrossRefGoogle Scholar

Carney, R., Cotter, J., Firth, J., et al. (2017). Cannabis use and symptom severity in individuals at ultra high risk for psychosis: A meta-analysis. Acta Psychiatr Scand, 136, 5–15.Google Scholar

Celofiga, A., Koprivsek, J., and Klavz, J. (2014). Use of synthetic cannabinoids in patients with psychotic disorders: case series. J Dual Diagn, 10, 168–173.CrossRefGoogle ScholarPubMed

Compton, M. T., Kelley, M. E., Ramsay, C. E., et al. (2009). Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry, 166, 1251–1257.Google Scholar

Compton, W. M., Han, B., Jones, C. M., et al. (2019). Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. Drug Alcohol Depend, 204, 107468.Google Scholar

Corkin, S., Milner, B., and Rasmussen, T. (1964). Effects of different cortical excisions on sensory thresholds in man. Trans Am Neurol Assoc, 89, 112–116.Google Scholar

D’Souza, D. C., Abi-Saab, W. M., Madonick, S., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry, 57, 594–608.Google Scholar

D’Souza, D. C., Ranganathan, M., Braley, G., et al. (2008). Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology, 33, 2505–2516.CrossRefGoogle ScholarPubMed

Davies, C., Wilson, R., Appiah-Kusi, E., et al. (2020). A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. Transl Psychiatry, 10, 311.Google Scholar

Dekker, N., Linszen, D., and De Haan, L. (2009). Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology, 42, 350–360.Google Scholar

Di Forti, M., Morgan, C., Dazzan, P., et al. (2009). High-potency cannabis and the risk of psychosis. Br J Psychiatry, 195, 488–491.Google Scholar

Dixon, L., Haas, G., Weiden, P., et al. (1990). Acute effects of drug abuse in schizophrenic patients: Clinical observations and patients’ self-reports. Schizophr Bull, 16, 69–79.CrossRefGoogle ScholarPubMed

Dixon, L., Haas, G., Weiden, P. J., et al. (1991). Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am J Psychiatry, 148, 224–230.Google Scholar

Elsohly, M. A., and Slade, D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci, 78, 539–548.Google Scholar

Fazio, R., and Zanna, M. (1981). Direct experience and attitude–behavior consistency. In Berkowitz, L. (ed.) Advances in Experimental Social Psychology (pp. 161–186). Chicago: University of Chicago Press.Google Scholar

Ferdinand, R. F., Sondeijker, F., van der Ende, J., et al. (2005). Cannabis use predicts future psychotic symptoms, and vice versa. Addiction, 100, 612–618.Google Scholar

Fishbein, M. (1980). A theory of reasoned action: Some applications and implications. Nebr Symp Motiv, 27, 65–116.Google Scholar

Fowler, I., Carr, V., Carter, N., et al. (1998). Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull, 24, 443–455.Google Scholar

Gearon, J. S., Bellack, A. S., Rachbeisel, J., et al. (2001). Drug-use behavior and correlates in people with schizophrenia. Addict Behav, 26, 51–61.CrossRefGoogle ScholarPubMed

Gordon, M. (1986). Microprocessor-based assessment of attention deficit disorders (ADD). Psychopharmacol Bull, 22, 288–290.Google Scholar

Goswami, S., Mattoo, S. K., Basu, D., et al. (2004). Substance-abusing schizophrenics: Do they self-medicate? Am J Addict, 13, 139–150.CrossRefGoogle ScholarPubMed

Grech, A., Van Os, J., Jones, P. B., et al. (2005). Cannabis use and outcome of recent onset psychosis. Eur Psychiatry, 20, 349–353.Google Scholar

Green, A. I., Tohen, M. F., Hamer, R. M., et al. (2004). First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol. Schizophr Res, 66, 125–135.Google Scholar

Green, B., Kavanagh, D. J., and Young, R. M. (2004). Reasons for cannabis use in men with and without psychosis. Drug Alcohol Rev, 23, 445–453.Google Scholar

Green, B., Young, R., and Kavanagh, D. (2005). Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry, 187, 306–313.Google Scholar

Gregg, L., Barrowclough, C., and Haddock, G. (2009). Development and validation of a scale for assessing reasons for substance use in schizophrenia: The ReSUS scale. Addict Behav, 34, 830–837.Google Scholar

Hambrecht, M., and Hafner, H. (1996). Substance abuse and the onset of schizophrenia. Biol Psychiatry, 40, 1155–1163.Google Scholar

Hasin, D. S. (2018). U.S. epidemiology of cannabis use and associated problems. Neuropsychopharmacology, 43, 195–212.Google Scholar

Hekimian, L. J., and Gershon, S. (1968). Characteristics of drug abusers admitted to a psychiatric hospital. JAMA, 205, 125–130.Google Scholar

Henquet, C., Krabbendam, L., Spauwen, J., et al. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ, 330, 11.Google Scholar

Henquet, C., van Os, J., Kuepper, R., et al. (2010). Psychosis reactivity to cannabis use in daily life: An experience sampling study. Br J Psychiatry, 196, 447–453.Google Scholar

Henquet, C., Rosa, A., Krabbendam, L., et al. (2006). An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology, 31, 2748–2757.Google Scholar

Hides, L., Baker, A., Norberg, M., et al. (2020). A web-based program for cannabis use and psychotic experiences in young people (keep it real): Protocol for a randomized controlled trial. JMIR Res Protoc, 9, e15803.Google Scholar

Hindocha, C., Quattrone, D., Freeman, T. P., et al. (2020). Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users? Transl Psychiatry, 10, 143.Google Scholar

Kapur, S., Mizrahi, R., and Li, M. (2005). From dopamine to salience to psychosis: Linking biology, pharmacology and phenomenology of psychosis. Schizophr Res, 79, 59–68.Google Scholar

Kay, S. R., Opler, L. A., and Fiszbein, A. (1986). Significance of positive and negative syndromes in chronic schizophrenia. Br J Psychiatry, 149, 439–448.Google Scholar

Kessler, R. C., Chiu, W. T., Demler, O., et al. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 62, 617–627.CrossRefGoogle ScholarPubMed

Khokhar, J. Y., Dwiel, L. L., Henricks, A. M., et al. (2018). The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr Res, 194, 78–85.Google Scholar

Knudsen, P., and Vilmar, T. (1984). Cannabis and neuroleptic agents in schizophrenia. Acta Psychiatr Scand, 69, 162–174.Google Scholar

Kolliakou, A., Castle, D., Sallis, H., et al. (2015). Reasons for cannabis use in first-episode psychosis: Does strength of endorsement change over 12 months? Eur Psychiatry, 30, 152–159.Google Scholar

Konings, M., and Maharajh, H. D. (2006). Cannabis use and mood disorders: Patterns of clinical presentations among adolescents in a developing country. Int J Adolesc Med Health, 18, 221–233.Google Scholar

Koskinen, J., Lohonen, J., Koponen, H., et al. (2010). Rates of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophr Bull, 36, 1115–1124.Google Scholar

Kraan, T., Velthorst, E., Koenders, L., et al. (2016). Cannabis use and transition to psychosis in individuals at ultra-high risk: Review and meta-analysis. Psychol Med, 46, 673–681.Google Scholar

Leweke, F., Koethe, D., and Gerth, C. (2005). Cannabidiol as an antipsychotic: A double-blind, controlled clinical trial of cannabidiol versus amisulpiride in acute schizophrenia. 15th Annual Symposium on Cannabinoids. Clearwater Beach, FL, Cannabinoid Research Society.Google Scholar

Leweke, F. M., Piomelli, D., Pahlisch, F., et al. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry, 2, e94.CrossRefGoogle ScholarPubMed

Linszen, D., and van Amelsvoort, T. (2007). Cannabis and psychosis: An update on course and biological plausible mechanisms. Curr Opin Psychiatry, 20, 116–120.Google Scholar

Linszen, D. H., Dingemans, P. M., and Lenior, M. E. (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry, 51, 273–279.Google Scholar

Lowe, D. J. E., Sasiadek, J. D., Coles, A. S., et al. (2019). Cannabis and mental illness: A review. Eur Arch Psychiat Clin Neurosci, 269, 107–120.Google Scholar

Mane, A., Fernandez-Exposito, M., Berge, D., et al. (2015). Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. Psychiatry Res, 229, 70–74.Google Scholar

Mason, O., Morgan, C. J., Dhiman, S. K., et al. (2009). Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychol Med, 39, 951–956.Google Scholar

Mauri, M., Volonteri, L., De Gaspari, I., et al. (2006). Substance abuse in first-episode schizophrenic patients: A retrospective study. Clin Pract Epidemiol Mental Health 2, 1–8.Google Scholar

McCreadie, R. G. (2002). Use of drugs, alcohol and tobacco by people with schizophrenia: Case-control study. Br J Psychiatry, 181, 321–325.Google Scholar

McHugh, M. J., McGorry, P. D. Yung, A. R., et al. (2017). Cannabis-induced attenuated psychotic symptoms: Implications for prognosis in young people at ultra-high risk for psychosis. Psychol Med, 47, 616–626.Google Scholar

Missouri Department of Health and Senior Services. (2010). Health Advisory: K2 Synthetic Marijuana Use among Teenagers and Young Adults in Missouri. Jefferson City, MO: Missouri Department of Health and Senior Services.Google Scholar

Morgan, C. J., and Curran, H. V. (2008). Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry, 192, 306–307.Google Scholar

Muller, H., Sperling, W., Kohrmann, M., et al. (2010). The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res, 118, 309–310.Google Scholar

Myin-Germeys, I., Krabbendam, L., Jolles, J., et al. (2002). Are cognitive impairments associated with sensitivity to stress in schizophrenia? An experience sampling study. Am J Psychiatry, 159, 443–449.Google Scholar

Myin-Germeys, I., van Os, J., Schwartz, J., et al. (2001). Emotional reactivity to daily life stress in psychosis. Arch Gen Psychiatry, 58, 1137–1144.Google Scholar

Myles, H., Myles, N., and Large, M. (2016). Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Aust NZ J Psychiatry, 50, 208–219.Google Scholar

Negrete, J. C., Knapp, W. P., Douglas, D. E., et al. (1986). Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. Psychol Med, 16, 515–520.Google Scholar

van Os, J., Bak, M., Hanssen, M., et al. (2002). Cannabis use and psychosis: A longitudinal population-based study. Am J Epidemiol, 156, 319–327.Google Scholar

Peralta, V., and Cuesta, M. J. (1992). Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr Scand, 85, 127–130.Google Scholar

Peters, B., de Koning, P., Dingemans, P., et al. (2009). Subjective effects of cannabis before the first psychotic episode. Aust NZ J Psychiatry, 43, 1155–1162.CrossRefGoogle ScholarPubMed

Rabin, R. A., and George, T. P. (2017). Understanding the link between cannabinoids and psychosis. Clin Pharmacol Ther, 101, 197–199.Google Scholar

Rabinowitz, J., Bromet, E. J. Lavelle, J., et al. (1998). Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol Med, 28, 1411–1419.Google Scholar

Raine, A. (1991). The SPQ: A scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull, 17, 555–564.Google Scholar

Ramaekers, J. G., Kauert, G., Theunissen, E. L., et al. (2009). Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol, 23, 266–277.Google Scholar

Regier, D., Farmer, M., Rae, D., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study [comment]. JAMA, 264, 2511–2518.Google Scholar

Ringen, P., Lagerberg, T., Birkenaes, A., et al. (2008). Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychol Med, 38, 1241–1249.Google Scholar

Rottanburg, D., Robins, A. H., Ben-Arie, O., et al. (1982). Cannabis-associated psychosis with hypomanic features. Lancet, 2, 1364–1366.Google Scholar

Santesteban Echarri, O., Kim, G., Haffey, P., et al. (2021). LooseLeaf, a mobile-based application to monitor cannabis use and cannabis-related experiences for youth at clinical high-risk for psychosis: Development and user acceptance testing. Int J Hum–Comp Interact, 37, 501–511.Google Scholar

Schofield, D., Tennant, C., Nash, L., et al. (2006). Reasons for cannabis use in psychosis. Aust NZ J Psychiatry, 40, 570–574.Google Scholar

Schwarcz, G., Karajgi, B., and McCarthy, R. (2009). Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. J Clin Psychopharmacol, 29, 255–258.Google Scholar

Silver, H., and Abboud, E. (1994). Drug abuse in schizophrenia: Comparison of patients who began drug abuse before their first admission with those who began abusing drugs after their first admission. Schizophr Res, 13, 57–63.Google Scholar

Solomons, K., Neppe, V. M., and Kuyl, J. M. (1990). Toxic cannabis psychosis is a valid entity. S Afr Med J, 78, 476–481.Google Scholar

Spencer, C., Castle, D., and Michie, P. T. (2002). Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull, 28, 233–247.Google Scholar

Stefanis, N. C., Delespaul, P., Henquet, C., et al. (2004). Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction, 99, 1333–1341.Google Scholar

Stirling, J., Barkus, E. J., Nabosi, L., et al. (2008). Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology, 41, 371–378.Google Scholar

Swartz, M., Wagner, H., Swanson, J., et al. (2006). Substance use in persons with schizophrenia: Baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis, 194, 164–172.Google Scholar

Test, M. A., Wallisch, L. S., Allness, D. J., et al. (1989). Substance use in young adults with schizophrenic disorders. Schizophr Bull, 15, 465–476.CrossRefGoogle ScholarPubMed

Thomas, B. F., and Elsohly, M. A. (2016). The botany of cannabis sativa L. In Thomas, B. F., and Elsohly, M. A. (eds.) The Analytical Chemistry of Cannabis (pp. 1–26). Amsterdam: Elsevier.Google Scholar

Treffert, D. A. (1978). Marijuana use in schizophrenia: A clear hazard. Am J Psychiatry, 135, 1213–1215.Google Scholar

Vadhan, N. P., Corcoran, C. M., Bedi, G., et al. (2017). Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study. Psychiatry Res, 257, 372–374.Google Scholar

Vearrier, D., and Osterhoudt, K. C. (2010). A teenager with agitation: Higher than she should have climbed. Pediatr Emerg Care, 26, 462–465.Google Scholar

Veen, N. D., Selten, J. P., van der Tweel, I., et al. (2004). Cannabis use and age at onset of schizophrenia. Am J Psychiatry, 161, 501–506.Google Scholar

Wainberg, M., Jacobs, G. R., di Forti, M., et al. (2021). Cannabis, schizophrenia genetic risk, and psychotic experiences: A cross-sectional study of 109,308 participants from the UK Biobank. Transl Psychiatry, 11, 211.Google Scholar

Warner, R., Taylor, D., Wright, J., et al. (1994). Substance use among the mentally ill: Prevalence, reasons for use, and effects on illness. Am J Orthopsychiatry, 64, 30–39.Google Scholar

Weil, A. T. (1970). Adverse reactions to marihuana. Classification and suggested treatment. N Engl J Med, 282, 997–1000.Google Scholar

Wilson, R., Bossong, M. G., Appiah-Kusi, E., et al. (2019). Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis. Transl Psychiatry, 9, 203.Google Scholar

Zuardi, A., Crippa, J. A., Hallak, J., et al. (2009). Cannabidiol for the treatment of psychosis in Parkinson’s disease. J Psychopharmacol, 23, 979–983.Google Scholar

Zuardi, A. W., Hallak, J. E. Dursun, S. M., et al. (2006). Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol, 20, 683–686.Google Scholar

Zuardi, A. W., Morais, S. L. Guimaraes, F. S., et al. (1995). Antipsychotic effect of cannabidiol. J Clin Psychiatry, 56, 485–486.Google ScholarPubMed

Alvarez-Jimenez, M., Priede, A., Hetrick, S. E., et al. (2012). Risk factors for relapse following treatment for first episode psychosis: A systematic review and meta-analysis of longitudinal studies. Schizophr Res, 139, 116–128.Google Scholar

Arseneault, L., Cannon, M., Witton, J., et al. (2004). Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry, 184, 110–117.Google Scholar

Bowers, M. B. (1977). Psychoses precipitated by psychotomimetic drugs: A follow-up study. Arch Gen Psychiatry, 34, 832–835.Google Scholar

D’Souza, D. C., Abi-Saab, W. M., Madonick, S., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry, 57, 594–608.Google Scholar

Di Forti, M., Quattrone, D., Freeman, T. P., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry, 6, 427–436.CrossRefGoogle ScholarPubMed

Emsley, R., Asmal, L., Rubio, J. M., et al. (2020). Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia. Schizophr Res, 225, 55–62.Google Scholar

Ferraro, L., Russo, M., O’Connor, J., et al. (2013). Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res, 150, 129–135.Google Scholar

Foglia, E., Schoeler, T., Klamerus, E., et al. (2017). Cannabis use and adherence to antipsychotic medication: A systematic review and meta-analysis. Psychol Med, 47, 1691–1705.Google Scholar

Foti, D. J., Kotov, R., Guey, L. T., et al. (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry, 167, 987–993.Google Scholar

Gonzalez-Pinto, A., Alberich, S., Barbeito, S., et al. (2011). Cannabis and first-episode psychosis: Different long-term outcomes depending on continued or discontinued use. Schizophr Bull, 37, 631–639.Google Scholar

Henquet, C., van Os, J., Kuepper, R., et al. (2010). Psychosis reactivity to cannabis use in daily life: An experience sampling study. Br J Psychiatry, 196, 447–453.Google Scholar

Hindocha, C., Freeman, T. P., Ferris, J. A., et al. (2016). No smoke without tobacco: A global overview of cannabis and tobacco routes of administration and their association with intention to quit. Front Psychiatry, 7, 104.Google Scholar

Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Rev Psychiatry, 4, 231–244.Google Scholar

Korver, N., Nieman, D. H., Becker, H. E., et al. (2010). Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. Aust NZ J Psychiatry, 44, 230–236.CrossRefGoogle ScholarPubMed

Liem-Moolenaar, M., te Beek, E. T., de Kam, M. L., et al. (2010). Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol, 24, 1697–1708.Google Scholar

Myles, H., Myles, N., and Large, M. (2016). Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Aust NZ J Psychiatry, 50, 208–219.Google Scholar

Ouellet-Plamondon, C., Abdel-Baki, A., Salvat, É., et al. (2017). Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes. Psychol Med, 47, 2461–2471.Google Scholar

Pelayo-Terán, J. M., Diaz, F. J., Pérez-Iglesias, R., et al. (2014). Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychol Med, 44, 37–50.Google Scholar

Potter, D. J., Clark, P., and Brown, M. B. (2008). Potency of Δ 9-THC and other cannabinoids in cannabis in England in 2005: Implications for psychoactivity and pharmacology. J Forens Sci, 53, 90–94.Google Scholar

Reid, S., and Bhattacharyya, S. (2019). Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: A systematic review. Psychiatry Res, 280, 112523.Google Scholar

Scheffler, F., Phahladira, L., Luckhoff, H., et al. (2021). Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment. Psychiatry Res, 302, 114022.Google Scholar

Schimmelmann, B. G., Conus, P., Cotton, S., et al. (2012). Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. Eur Psychiatry, 27, 463–469.Google Scholar

Schoeler, T., Kambeitz, J., Behlke, I., et al. (2016a). The effects of cannabis on memory function in users with and without a psychotic disorder: Findings from a combined meta-analysis. Psychol Med, 46, 177–188.Google Scholar

Schoeler, T., Monk, A., Sami, M. B., et al. (2016b). Continued versus discontinued cannabis use in patients with psychosis: A systematic review and meta-analysis. Lancet Psychiatry, 3, 215–225.Google Scholar

Schoeler, T., Petros, N., Di Forti, M., et al. (2016c). Association between continued cannabis use and risk of relapse in first-episode psychosis: A quasi-experimental investigation within an observational study. JAMA Psychiatry, 73, 1173–1179.Google Scholar

Schoeler, T., Petros, N., Di Forti, M., et al. (2016d). Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: An observational study. Lancet Psychiatry, 3, 947–953.Google Scholar

Schoeler, T., Petros, N., Di Forti, M., et al. (2017). Effect of continued cannabis use on medication adherence in the first two years following onset of psychosis. Psychiatry Res, 255, 36–41.Google Scholar

Setién-Suero, E., Neergaard, K., Ortiz-García de la Foz, V., et al. (2019). Stopping cannabis use benefits outcome in psychosis: Findings from 10-year follow-up study in the PAFIP-cohort. Acta Psychiatr Scand, 140, 349–359.Google Scholar

Wilson, R., and Bhattacharyya, S. (2016). Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review. J Psychopharmacol, 30, 99–111.Google Scholar

Abdel-Baki, A., Thibault, D., Medrano, S., et al. (2020). Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder. Early Interv Psychiatry, 14, 69–79.Google Scholar

Adamson, S., Kay-Lambkin, F., Baker, A., et al. (2010). An improved brief measure of cannabis misuse: The cannabis use disorders identification test – revised (CUDIT-R). Drug Alcohol Depend, 110, 137–143.Google Scholar

Allsop, D., Copeland, J., Linteris, N., et al. (2014). Nabiximols as an agonist replacement therapy during cannabis withdrawal: A randomized clinical trial. JAMA Psychiatry, 71, 281–291.Google Scholar

Arsalan, A., Iqbal, Z., Tariq, M., et al. (2019). Association of smoked cannabis with treatment resistance in schizophrenia. Psychiatry Res, 278, 242–247.Google Scholar

Baker, A., Bucci,, S., Lewin, T. J., et al. (2006). Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial. Br J Psychiatry, 188, 439–448.Google Scholar

Barrowclough, C., Haddock, G., Tarrier, N., et al. (2001). Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry, 158, 1706–1713.Google Scholar

Barrowclough, C., Marshall, M., Gregg, L., et al. (2014). A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: A randomized controlled trial. Psychol Med, 44, 2749–2761.Google Scholar

Bellamoli, E., Manganotti, P., Schwartz, R. P., et al. (2014). rTMS in the treatment of drug addiction: An update about human studies. Behav Neurol, 2014, 815215.Google Scholar

Bersani, G., Orlandi, V., Kotzalidis, G. D., et al. (2002). Cannabis and schizophrenia: Impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci, 252, 86–92.Google Scholar

Bloomfield, M. A., Morgan, C. J., Kapur, S., et al. (2014). The link between dopamine function and apathy in cannabis users: An [18F]-DOPA PET imaging study. Psychopharmacology (Berl), 231, 2251–2259.Google Scholar

Bonsack, C., Gibellini Manetti, S., Favrod, J., et al. (2011) Motivational intervention to reduce cannabis use in young people with psychosis: A randomized controlled trial. Psychother Psychosom, 80, 287–297.Google Scholar

Borgan, F., Kokkinou, M., and Howes, O. (2021). The cannabinoid CB₁ receptor in schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging, 6, 646–659.Google Scholar

Brunette, M. F., Dawson, R., O’Keefe, C. D., et al. (2011). A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagnosis, 7, 50–63.Google Scholar

Bucci, S., Baker, A., Halpin, S. A., et al. (2010). Intervention for cannabis use in young people at ultra high risk for psychosis and in early psychosis. Mental Health Subst Use, 3, 66–73.Google Scholar

Budney, A. J., Moore, B. A., Rocha, H. L., et al. (2006). Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol, 74, 307–316.Google Scholar

Carpenter, K. M., McDowell, D., Brooks, D. J., et al. (2009). A preliminary trial: Double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict, 18, 53–64.Google Scholar

Carroll, K. M., Easton, C. J., Nich, C., et al. (2006). The use of contingency management and motivational/skills-building therapy to treat young adults with marijuana dependence. J Consult Clin Psychol, 74, 955–966.Google Scholar

Coles, A. S., Knezevic, D., George, T. P., et al. (2021). Long-acting injectable antipsychotic treatment in schizophrenia and co-occurring substance use disorders. Front Psychiatry, 12, 808002.Google Scholar

Coles, A. S., Kozak, K., and George, T. P. (2018). A review of brain stimulation for treatment of substance use disorders. Am J Addict, 27, 71–91.Google Scholar

Coles, A. S., Sasiadek, J., and George, T. P. (2019) Pharmacotherapies for co-occurring substance use and bipolar disorders: A systematic review. Bipolar Dis, 21, 595–610.CrossRefGoogle ScholarPubMed

Compton, M. T., Furman, A. C., and Kaslow, N. J. (2004). Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: Preliminary evidence from an African American first-episode sample. Schizophr Res, 71, 61–64.Google Scholar

Cooper, Z. D., Foltin, R. W., Hart, C. L., et al. (2013). A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol, 18, 993–1002.Google Scholar

Copeland, J., Swift, W., Roffman, R., et al. (2001). A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat, 21, 55–64; discussion 65–66.Google Scholar

D’Souza, D. C., Abi-Saab, W. M., Madonick, S., et al. (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry, 57, 594–608.Google Scholar

D’Souza, D. C., Cortes-Briones, J., Creatura, G., et al. (2019). Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: A double-blind, placebo-controlled, parallel-group, phase 2a single-site randomized trial. Lancet Psychiatry, 6, 35–45.Google Scholar

Diana, M., Raij, T., Melis, M., et al. (2017). Rehabilitating the addicted brain with transcranial magnetic stimulation. Nat Rev Neurosci, 18, 685–693.Google Scholar

Drake, R. E., and Mueser, K. T. (2001). Managing comorbid schizophrenia and substance abuse. Curr Psychiat Rep, 3, 418–422.Google Scholar

Drake, R. E., O’Neal, E. L., and Wallach, M. A. (2008). A systematic review of psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat, 34, 123–138.Google Scholar

Dunlop, K., Hanlon, C. A., and Downar, J. (2017). Noninvasive brain stimulation treatments for addiction and major depression. Ann NY Acad Sci, 1394, 31–54.Google Scholar

Eack, S. M., Hogarty, S. S., Greenwald, D. P., et al. (2015). Cognitive enhancement therapy in substance misusing schizophrenia: Results of an 18-month feasibility trial. Schizophr Res, 161, 478–483.Google Scholar

Edwards, J., Elkins, K., Hinton, M., et al. (2006). Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand, 114, 109–117.Google Scholar

Feil, J., and Zangen, A. (2010). Brain stimulation in the study and treatment of addiction. Neurosci Biobehav Rev, 34, 559–574.Google Scholar

Gates, P. J., Norberg, M. M., Copeland, J., et al. (2012). Randomized controlled trial of a novel cannabis use intervention delivered by telephone. Addiction, 107, 2149–2158.Google Scholar

George, T. P., Hill, K. P., and Vaccarino, F. J. (2018). Cannabis legalization and psychiatric disorders: Caveat H-emptor. Can J Psychiatry, 63, 447–450.Google Scholar

Gilbert, D. G., Rabinovich, N. E., and McDaniel, J. T. (2020). Nicotine patch for cannabis withdrawal symptom relief: A randomized controlled trial. Psychopharmacology (Berl), 237, 1507–1519.Google Scholar

Gorelick, D. A., Zangen, A., and George, M. S. (2014). Transcranial magnetic stimulation in the treatment of substance addiction. Ann NY Acad Sci, 1327, 79–93.Google Scholar

Gray, K. M., Carpenter, M. J., Baker, N. L., et al. (2012). A double-blind, randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry, 169, 805–812.Google Scholar

Gray, K. M., Sonne, S. C., McClure, E. A., et al. (2017). A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend, 177, 249–257.Google Scholar

Gray, K. M., Watson, N. L., Carpenter, M. J., et al. (2010). N-acetylcysteine (NAC) in young marijuana users: An open-label pilot study. Am J Addict, 19, 187–189.Google Scholar

Green, A. I. (2007). Treatment of schizophrenia and comorbid substance abuse: Pharmacological approaches. J Clin Psychiatry, 67, S31–S35.Google Scholar

Green, A. I., Burgess, E. S., Dawson, R., et al. (2003). Alcohol and cannabis use in schizophrenia: Effects of clozapine vs. risperidone. Schizophr Res, 60, 81–85.Google Scholar

Green, M. F. (2016). Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. J Clin Psychiatry, 77, 8–11.Google Scholar

Guillin, O., Abi-Dargham, A., and Laruelle, M. (2007). Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol, 78, 1–39.Google Scholar

Haddock, G., Barrowclough, C., Tarrier, C., et al. (2003). Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. Br J Psychiatry, 183, 418–426.Google Scholar

Hajizadeh, M. (2016). Legalizing and regulating marijuana in Canada: Review of potential economic, social, and health impacts. Int J Health Policy Manag, 5, 453–456.Google Scholar

Haney, M., Cooper, Z. D., Bedi, G., et al. (2013). Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology, 38, 1557–1565.Google Scholar

Haney, M., Hart, C. L., Vosburg, S. K., et al. (2010). Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl), 211, 233–244.Google Scholar

Haney, M., Ramesh, D, Glass, A, et al. (2015). Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Neuropsychopharmacology, 40, 2489–2498.Google Scholar

Hanlon, C. A., Dowdle, L. T., and Henderson, J. S. (2018). Modulating neural circuits with transcranial magnetic stimulation: Implications for addiction treatment development. Pharmacol Rev, 70, 661–683.Google Scholar

Hasin, D. S. (2018). U.S. epidemiology of cannabis use and associated problems. Neuropsychopharmacology, 43, 195–212.CrossRefGoogle ScholarPubMed

Hendriks, V., van der Schee, E., and Blanken, P. (2011). Treatment of adolescents with a cannabis use disorder: Main findings of a randomized controlled trial comparing multidimensional family therapy and cognitive behavioral therapy in The Netherlands. Drug Alcohol Depend, 119, 64–71.Google Scholar

Hill, K. P., Toto, L. H., Lukas, S. E., et al. (2013). Cognitive behavioral therapy and the nicotine transdermal patch for dual nicotine and cannabis dependence: A pilot study. Am J Addict, 22, 233–238.Google Scholar

Hjorthøj, C. R., Orlovska, S., Fohlmann, A., et al. (2013). Psychiatric treatment following participation in the CapOpus randomized trial for patients with comorbid cannabis use disorder and psychosis. Schizophr Res, 151, 191–196.Google Scholar

Hoch, E., Noack, R., Henker, J., et al. (2012). Efficacy of a targeted cognitive-behavioral treatment program for cannabis use disorders (CANDIS). Eur Neuropsychopharmacol, 22, 267–280.Google Scholar

Ikeda, T., Kobayashi, S., and Morimoto, C. (2019). Effects of repetitive transcranial magnetic stimulation on ER stress-related genes and glutamate, gamma-aminobutyric acid and glycine transporter genes in mouse brain. Biochem Biophys Rep, 17, 10–16.Google Scholar

James, W., Preston, N., Koh, G., et al. (2004). A group intervention which assists patients with dual diagnosis reduce their drug use: A randomized controlled trial. Psychol Med, 34, 983–990.CrossRefGoogle ScholarPubMed

Johnston, J., Lintzeris, N., Allsop, D. J., et al. (2014). Lithium carbonate in the management of cannabis withdrawal: A randomized placebo-controlled trial in an inpatient setting. Psychopharmacology (Berl), 231, 4623–4636.Google Scholar

Kadden, R. M., Litt, M. D., Kabela-Cormier, E., et al. (2007). Abstinence rates following behavioral treatments for marijuana dependence. Addict Behav, 32, 1220–1236.Google Scholar

Kavanagh, D. J., Young, R., White, A., et al. (2004). A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev, 23, 151–155.Google Scholar

Kolliakou, A., Castle, D., Sallis, H., et al. (2012). Reasons for cannabis use in first-episode psychosis: Does strength of endorsement change over 12 months? Eur Psychiatry, 30, 152–159.Google Scholar

Koskinen, J., Lohonen, J., Koponen, H., et al. (2010). Rates of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophr Bull, 36, 1115–1124.Google Scholar

Kozak, K., Barr, M. S., and George, T. P. (2017). Traits and biomarkers for addiction risk in schizophrenia. Curr Addict Rep, 4, 14–24.Google Scholar

Kozak, K., Lowe, D. J. E., Sanches, M., et al. (2021). Effects of repetitive transcranial magnetic stimulation (rTMS) on cannabis use and cognitive function in achizophrenia. Brain Stimulation, under review.Google Scholar

Krebs, P., Norcross, J. C., Nicholson, J. M., et al. (2018). Stages of change and psychotherapy outcomes: A review and meta-analysis. J Clin Psychol, 74, 1964–1979.CrossRefGoogle ScholarPubMed

Levin, F., Mariani, J., Brooks, D. J., et al. (2011). Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend, 116, 142–150.Google Scholar

Levin, F., Mariani, J, Brooks, D. J., et al. (2013). A randomized, double-blind, placebo-controlled trial of venlafaxine extended-release for co-occurring cannabis dependence and depressive disorders. Am J Addict, 108, 1084–1094.Google Scholar

Levin, F., Mariani, J. J., Pavlicova, M., et al. (2016). Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend, 159, 53–60.Google Scholar

Levin, F., McDowell, D., Evans, S. M., et al. (2004). Pharmacotherapy for marijuana dependence: A double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict, 13, 21–32.Google Scholar

Lintzeris, N., Bhardwaj, A., Mills, L., et al. (2019). Nabiximols for the treatment of cannabis dependence: A randomized clinical trial. JAMA Intern Med, 179, 1242–1253.Google Scholar

Litt, M. D., Kadden, R. M., Tennen, H., et al. (2020). Individualized assessment and treatment program (IATP) for cannabis use disorder: Randomized controlled trial with and without contingency management. Psychol Addict Behav, 34, 40–51.Google Scholar

Longenecker, J. M., Bagby, R. M., McKenzie, K. J., et al. (2021). Cross-cutting symptom domains predict functioning in psychotic disorders. J Clin Psychiatry, 82, 20m13288.Google Scholar

Lowe, D. J. E., Sasiadek, J. D., Coles, A. S., et al. (2019). Cannabis and mental illness: A review. Eur Arch Psychiat Clin Neurosci, 269, 107–120.Google Scholar

Machielsen, M., Beduin, A. S., Dekker, N., et al. (2012). Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol, 26, 89–95.Google Scholar

Machielsen, M. W. J., Veltman, D. J., van den Brink, W., et al. (2014). The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An FMRI study. J Psychopharmacol, 28, 633–642.Google Scholar

Madigan, K., Brennan, D., Lawlor, E., et al. (2013). A multi-center, randomized controlled trial of a group psychological intervention for psychosis with comorbid cannabis dependence over the early course of illness. Schizophr Res, 143, 138–142.Google Scholar

Mahoney, J. J., 3rd, Hanlon, C. A., Marshalek, P. J., et al. (2020). Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment. J Neurol Sci, 418, 117149.Google Scholar

Marijuana Treatment Project Research Group. (2004). Brief treatments for cannabis dependence: Findings from a randomized multisite trial. J Consult Clin Psychol, 72, 455–466.Google Scholar

Mason, B., Cream, R., Godell, V., et al. (2012). A proof-of-concept randomized controlled study of gabapentin: Effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology, 37, 1689–1698.Google Scholar

McLellan, A. T., Kushner, H., Metzger, D., et al. (1992). The fifth edition of the addiction severity index. J Subst Abus Treat, 9, 199–213.Google Scholar

McRae-Clark, A. L., Baker, N. L., Gray, K. M., et al. (2015). Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend, 156, 29–37.Google Scholar

McRae-Clark, A. L., Baker, N. L., Gray, K. M., et al. (2016). Vilazodone for cannabis dependence: A randomized, controlled pilot trial. Am J Addict, 25, 69–75.Google Scholar

McRae-Clark, A., Carter, R. E., Killeen, T. K., et al. (2009). A placebo-controlled trial of buspirone for the treatment of cannabis dependence. Drug Alcohol Depend, 105, 132–138.Google Scholar

McRae-Clark, A., Carter, R. E., Killeen, T. K., et al. (2010). A placebo-controlled trial of atomoxetine in marijuna-dependent individuals with attention deficit hyperactivity disorder. Am J Addict, 19, 481–489.Google Scholar

Miranda, R., Jr., Treloar, H., Blanchard, A., et al. (2017). Topiramate and motivational enhancement therapy for cannabis use among youth: A randomized placebo-controlled pilot study. Addict Biol, 22, 779–790.Google Scholar

Moretti, J., Poh, E. Z., and Rodger, J. (2020). rTMS-induced changes in glutamatergic and dopaminergic systems: Relevance to cocaine and methamphetamine use disorders. Front Neurosci, 14, 137.Google Scholar

Notzon, D. P., Kelly, M. A., Choi, C. J., et al. (2018). Open-label pilot study of injectable naltrexone for cannabis dependence. Am J Drug Alcohol Abuse, 44, 619–627.Google Scholar

Penetar, D. M., Looby, A. R., Ryan, E. T., et al. (2012). Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: A pilot study. Subst Abuse, 6, 63–71.Google Scholar

Potvin, S., Stip, E., Lipp, O., et al. (2006). Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: An open-label trial. Curr Med Res Opin, 22, 1277–1285.Google Scholar

Rabin, R. A., Barr, M. S., Herman, Y., et al. (2017). Effects of extended cannabis abstinence on neurocognitive outcomes in cannabis dependent schizophrenia patients versus non-psychiatric controls. Neuropsychopharmacology, 42, 2259–2271.Google Scholar

Rabin, R. A., and George, T. P. (2017). Understanding the link between cannabinoids and psychosis. Clin Pharmacol Therap, 101, 197–199.Google Scholar

Rabin, R. A., Kozak, K., Herman, Y., et al. (2018). A method to achieve short-term cannabis abstinence in cannabis-dependent patients with schizophrenia and non-psychiatric controls. Schizophr Res, 194, 47–54.Google Scholar

Rabin, R. A., Zakzanis, K. K., and George, T. P. (2011). The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. Schizophr Res, 128, 111–116.Google Scholar

Rooke, S., Copeland, J., Norberg, M., et al. (2013). Effectiveness of a self-guided web-based cannabis treatment program: Randomized controlled trial. J Med Internet Res, 15, e26.Google Scholar

Roten, A. T., Baker, N. L., and Gray, K. M. (2013). Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial. Addict Behav, 38, 1788–1791.Google Scholar

Salling, M. C., and Martinez, D. (2016). Brain stimulation in addiction. Neuropsychopharmacology, 41, 2798–2809.Google Scholar

Schnell, T., Koethe, D., Krasnianski, A., et al. (2014). Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: A randomized study. Am J Addict, 23, 308–312.Google Scholar

Schwilke, E. W., Gulberg, R. G., Darwin, W. D., et al. (2011). Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction, 106, 499–506.Google Scholar

Sheridan Rains, L., Marston, L., Hinton, M., et al. (2019). Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: The CIRCLE randomised clinical trial. BMC Med, 17, 161.Google Scholar

Sherman, B. J., Baker, N. L., and McRae-Clark, A. L. (2017). Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention. Psychiatry Res, 249, 318–320.Google Scholar

Sigmon, S. C., and Higgins, S. T. (2006). Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness. J Subst Abuse Treat, 30, 291–295.Google Scholar

Sigmon, S. C., Steingard, S., Badger, G. J., et al. (2000). Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: A feasibility study. Exp Clin Psychopharmacol, 8, 509–517.Google Scholar

Sinadinovic, K., Johansson, M., Johansson, A. S., et al. (2020). Guided web-based treatment program for reducing cannabis use: A randomized controlled trial. Addict Sci Clin Pract, 15, 9.Google Scholar

Slavet, J. D., Stein, L. A. R., Colby, S. M., et al. (2006). The marijuana ladder: Measuring motivation to change marijuana use in incarcerated adolescents. Drug Alcohol Depend, 83, 42–48.Google Scholar

Spencer, C., Castle, D., and Michie, P. T. (2002). Motivations that maintain substance use among individuals with psychotic disorders. Schizophr Bull, 28, 233–247.Google Scholar

Stephens, R. S., Babor, T. F., Kadden, R., et al. (2004). Brief treatments for cannabis dependence: Findings from a randomized multisite trial. J Consult Clin Psychol, 72, 455–466.Google Scholar

Stephens, R. S., Roffman, R. A., and Curtin, L. (2000). Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol, 68, 898–908.Google Scholar

Stephens, R. S., Roffman, R. A., and Simpson, E. E. (1994). Treating adult marijuana dependence: A test of the relapse prevention model. J Consult Clin Psychol, 62, 92–99.Google Scholar

Szerman, N., Basurte-Villamor, I., Vega, P., et al. (2020). Once-monthly long-acting injectable aripiprazole for the treatment of patients with schizophrenia and co-occurring substance use disorders: A multicentre, observational study. Drugs Real World Outcomes, 7, 75–83.Google Scholar

Tang, S. M., Ansarian, A., and Courtney, D. B. (2017). Clozapine treatment and cannabis use in adolescents with psychotic disorders: A retrospective cohort chart review. J Can Acad Child Adolesc Psychiatry, 26, 51–58.Google Scholar

Tatar, O., Abdel-Baki, A., Tra, C., et al. (2021). Technology-based psychological interventions for young adults with early psychosis and cannabis use disorder: Qualitative study of patient and clinician perspectives. JMIR Form Res, 5, e26562.Google Scholar

Trigo, J. M., Soliman, A., Quilty, L. C., et al. (2018). Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial. PLoS ONE, 13, e0190768.Google Scholar

Weinstein, A. M., Miller, H., Bluvstein, I., et al. (2014). Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: A double-blind placebo-controlled study. Am J Drug Alcohol Abuse, 40, 16–22.Google Scholar

Zhang, J. J. Q., Fong, K. N. K., Ouyang, R. G., et al. (2019). Effects of repetitive transcranial magnetic stimulation (rTMS) on craving and substance consumption in patients with substance dependence: A systematic review and meta-analysis. Addiction, 114, 2137–2149.Google Scholar